348169-39-1

Basic information

• Product Name: 4-BROMO-2-METHOXY-6-METHYLANILINE
• Synonyms: 4-BROMO-2-METHOXY-6-METHYLANILINE;2-AMino-5-broMo-3-Methylanisole[4-BroMo-2-Methoxy-6-MethylbenzenaMine];4-Bromo-2-methoxy-6-methylphenylamine
• CAS NO: 348169-39-1
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 216.08
• Mol File: 348169-39-1.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 271.037°C at 760 mmHg
• Flash Point: 117.719°C
• Appearance: /
• Density: 1.458g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: 2-8°C
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-2-METHOXY-6-METHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-METHOXY-6-METHYLANILINE(348169-39-1)
• EPA Substance Registry System: 4-BROMO-2-METHOXY-6-METHYLANILINE(348169-39-1)

Safety Data

• Hazardous Substances Data: 348169-39-1(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-methoxy-6-methylaniline is an organic compound with the molecular formula C8H10BrNO. It is a derivative of aniline, in which a bromine atom is attached to the fourth carbon, a methoxy group is attached to the second carbon, and a methyl group is attached to the sixth carbon. It is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds. This chemical has potential applications in medicinal chemistry and the development of new drugs due to its unique chemical structure. However, it is important to handle this compound with caution, as it may pose health hazards if not properly handled or disposed of.

InChI:InChI=1/C8H10BrNO/c1-5-3-6(9)4-7(11-2)8(5)10/h3-4H,10H2,1-2H3

Upstream product

• 50868-73-0 2-methoxy-6-methylbenzeneamine 

Downstream Products

• 29578-83-4 3-bromo-5-methoxytoluene 
• 1357103-83-3 C₈H₈BrN₂O⁽¹⁺⁾*Cl^(1-) 
• 943827-00-7 4-[4-(4-bromo-2-methyl-6-methoxyphenylamino)pyrimidin-4-ylamino]benzonitrile 
• 171102-68-4 2-fluoro-6-[(3-methyl-5-methoxyphenyl)thio]benzonitrile 
• 348169-31-3 2-fluoro-6-(3-hydroxy-5-methyl-benzenesulfonyl)-benzonitrile 
• 171102-69-5 2-fluoro-6-[(3-methyl-5-methoxyphenyl)-sulfonyl]benzonitrile 
• 171102-57-1 2-amino-6-[(3-methyl-5-methoxyphenyl)sulfonyl]benzonitrile 
• 348169-32-4 2-(3-ethoxy-5-methylphenylsulfonyl)-2-fluorobenzonitrile 
• 348169-33-5 2-fluoro-6-(3-methyl-5-propoxy-benzenesulfonyl)-benzonitrile 
• 348169-34-6 2-(3-butoxy-5-methyl-benzenesulfonyl)-6-fluoro-benzonitrile 
• 725251-81-0 (5-methoxy-3-methylphenyl)boronic acid 

Relevant articles and documents

5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS

The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.

N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds.

Discovery of a 7-arylaminobenzimidazole series as novel CRF1receptor antagonists

A promising lead compound 1 of a benzimidazole series has been identified as a corticotropin-releasing factor 1 (CRF1) receptor antagonist. In this study, we focused on replacement of a 7-alkylamino group of 1, predicted to occupy a large lipophilic pocket of a CRF1receptor, with an aryl group. During the course of this examination, we established new synthetic approaches to 2,7-diarylaminobenzimidazoles. The novel synthesis of 7-arylaminobenzimidazoles culminated in the identification of compounds exhibiting inhibitory activities comparable to the alkyl analog 1. A representative compound, p-methoxyanilino analog 16g, showed potent CRF binding inhibitory activity against a human CRF1receptor and human CRF1receptor antagonistic activity (IC50?=?27?nM, 56?nM, respectively). This compound exhibited ex vivo125I-Tyr0(125I-CRF) binding inhibitory activity in mouse frontal cortex, olfactory bulb, and pituitary gland at 20?mg/kg after oral administration. In this report, we discuss the structure–activity-relationship of these 7-arylamino-1H-benzimidazoles and their synthetic method.